Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -3 of 3 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				CASA404A2301 NCT00662597


2.		A Study of ASA404 or Placebo in Combination With Docetaxel in Second-Line Treatment for (Stage IIIb/IV) Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Approved-not yet active				18 and over				Pharmaceutical / Industry				CASA404A2302 EUDRACT number: 2008-002309-38, NCT00738387


3.		An Open-Label, Phase I Trial of Intravenous ASA404 Administered in Combination With Paclitaxel and Carboplatin in Japanese Patients With Non-Small Cell Lung Cancer (NSCLC)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				20 and over				Pharmaceutical / Industry				CASA404A1101 NCT00674102

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute